Carthera Revenue and Competitors
Estimated Revenue & Valuation
- Carthera's estimated annual revenue is currently $2.7M per year.
- Carthera's estimated revenue per employee is $98,000
Employee Data
- Carthera has 28 Employees.
- Carthera grew their employee count by 12% last year.
Carthera's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
Carthera Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.2M | 3 | -50% | N/A | N/A |
#2 | $13.6M | 97 | -9% | N/A | N/A |
#3 | $30.8M | 200 | 29% | N/A | N/A |
#4 | $2.4M | 141 | 8% | N/A | N/A |
#5 | $42.7M | 277 | 13% | N/A | N/A |
#6 | $3.7M | 33 | 14% | N/A | N/A |
#7 | $8.4M | 67 | 5% | N/A | N/A |
#8 | $1.6M | 19 | N/A | N/A | N/A |
#9 | $4M | 36 | -8% | N/A | N/A |
#10 | $41M | 266 | 12% | N/A | N/A |
What Is Carthera?
CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders since 2010. The company's proprietary device called SonoCloud® is an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB) and allows a significantly increased concentration of therapeutic molecules to reach the brain. A Phase 1/2a clinical trial is underway in glioblastoma while the new treatment option could be suitable for a wide range of other indications, including Alzheimer's disease.
keywords:N/AN/A
Total Funding
28
Number of Employees
$2.7M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Carthera News
Paris, France-based Carthera is reporting that SonoCloud, its ultrasound-based medical device targeting a wide range of brain diseases,...
Carthera demonstrates potential of Sonocloud for lowering amyloid load in Alzheimer's patients · Blood-brain barrier limits active drug...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.8M | 28 | N/A | N/A |
#2 | $3.2M | 28 | N/A | N/A |
#3 | $2.8M | 28 | N/A | N/A |
#4 | $2.7M | 28 | N/A | N/A |
#5 | $2.2M | 28 | -24% | $20M |